Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-Naïve Melanoma: Implications for Clinical Trials

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-4011
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Novel Cardiovascular Biomarkers and Implications for Clinical Trials

Nature Clinical Practice Cardiovascular Medicine
2006English

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma

Frontiers in Immunology
AllergyImmunology
2019English

Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-Checkpoint Inhibitor Treatment for Malignant Melanoma

In Vivo
BiochemistryMedicineGeneticsPharmacologyMolecular Biology
2018English

Immune Checkpoint Inhibitors in Melanoma: Review and Update

Journal of the Portuguese Society of Dermatology and Venereology
2018English

H3K27me3 and EZH2 Expression in Melanoma: Relevance for Melanoma Progression and Response to Immune Checkpoint Blockade

Clinical Epigenetics
GeneticsDevelopmental BiologyMolecular Biology
2020English

Treatment Targets in Conjunctival Melanoma

Acta Ophthalmologica
MedicineOphthalmology
2018English

Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma

Frontiers in Immunology
AllergyImmunology
2018English

Is There a Role for Immune Checkpoint Blockade in Metastatic Uveal Melanoma?

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2015English

Considerations for Combined Immune Checkpoint Modulation and Radiation Treatment

Radiation Research
Nuclear MedicineRadiologyRadiationImagingBiophysics
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy